Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma

Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma

Abstract Tirabrutinib (ONO/GS-4059; Ono Pharmaceutical) is a newly developed drug that selectively and irreversibly inhibits Bruton’s tyrosine kinase (BTK) and has been approved in Japan for treating relapsed/refractory primary central nervous system lymphoma (PCNSL). However, its therapeutic effect...

Full description

Bibliographic Details
Main Authors: Yoshiko Okita, Rieko Kano-Fujiwara, Shin-Ichi Nakatsuka, Keiichiro Honma, Manabu Kinoshita
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Experimental Hematology & Oncology
Subjects:
Primary central nervous system lymphoma
Tirabrutinib
Bruton’s tyrosine kinase inhibitor
Autopsy
Online Access:https://doi.org/10.1186/s40164-021-00222-5

Internet

https://doi.org/10.1186/s40164-021-00222-5

Similar Items